1976 to 2026: Thymalin has had 50 years and no trial
The oldest record the importer found for Thymalin is from 1976. The newest is 2026. That is…
Members only. Join to read the rest
For Research & Educational Discussion Only. Not Medical Advice
Polypeptide fraction extracted from calf thymus
Also known as Thymus extract, Timalin
Not a defined molecule but a thymic extract, with a clinical literature that is almost entirely from one national research tradition and essentially no presence in the international trial registry.
This entry is preclinical
In shortAn extract of calf thymus, developed in the Soviet Union and still used clinically in Russia and neighbouring states. It is not a single defined peptide, and that matters more here than anywhere else: what is in it depends on how it was extracted, so two products under the same name are not necessarily the same thing. Almost the whole literature comes from one research tradition.
Thymalin is a preparation of low-molecular-weight polypeptides extracted from calf thymus, developed in the Soviet Union and still used clinically in Russia and neighbouring states. It is not a single defined peptide, and that distinction matters more here than anywhere else in this compendium: the composition depends on the extraction, so two products under the same name are not necessarily the same thing.
There is a substantial literature, a few hundred papers, much of it reporting immunomodulatory and geroprotective effects. Almost all of it comes from a single research tradition, much of it is not in English, and the trial registry returns essentially nothing.
In shortThe proposal is that supplying thymus peptide signals restores immune function that declines with age, by influencing how immune cells mature. Because the preparation is a mixture rather than a single molecule, mechanism claims are harder to test than usual: attributing an effect to a specific peptide means isolating it, and the published work largely does not.
Proposed to restore thymic-dependent immune function by supplying thymic peptide signals, influencing T-lymphocyte differentiation and maturation.
Because the preparation is a mixture rather than a molecule, mechanism claims are harder to test than usual. Attributing an effect to a specific peptide requires isolating it, and the published work largely does not.
In shortDifficult to assess honestly, and that is a finding rather than a hedge. Clinical reports exist, including long-running studies of elderly groups claiming effects on illness and survival. They come almost exclusively from one group in one country and have not been independently replicated. The usual ways of checking them have not been applied.
Difficult to assess honestly, and this entry is a good example of why that is a finding rather than a hedge.
Clinical reports exist, including long-running studies of elderly cohorts claiming effects on morbidity and survival. They come almost exclusively from one group of researchers in one country, are frequently published in journals that are hard to access or evaluate from outside, and have not been replicated independently.
That is not evidence that the claims are wrong. It is a statement that the usual mechanisms for checking them have not been applied. Anyone citing the survival findings should say where they come from.
In shortReported as well tolerated in the Russian clinical literature at the doses used there. The specific risk here is not unusual toxicity, it is the preparation itself: an extract of animal tissue carries immune-reaction and contamination considerations a synthetic peptide does not, and those depend on manufacturing standards that cannot be verified from outside.
Reported as well tolerated in the Russian clinical literature, at the doses and durations used there.
The specific risk here is not idiosyncratic toxicity, it is the preparation itself. An extract of animal tissue carries immunogenicity and contamination considerations that a synthetic peptide does not, and those depend entirely on manufacturing standards that are not verifiable from outside for grey-market product.
In shortRegistered as a medicine in Russia and some neighbouring states. Not approved in the US, the EU, the UK or Australia. Because the product is defined by how it is extracted rather than by its structure, a buyer has no straightforward way to confirm it is the same preparation the literature describes.
Registered as a medicine in Russia and some neighbouring states. Not approved in the United States, the European Union, the United Kingdom or Australia.
Material sold internationally under this name is research-use-only, and given that the product is defined by its extraction rather than its structure, there is no straightforward way for a buyer to confirm it is the same preparation the literature describes.
2 studies indexed. Findings and limitations get equal weight, on purpose.
Members area
Everything above is free to read. What an account opens is the evidence underneath it: 2 studies with their limitations, and the regimen each trial actually reported.
Free to create. A membership is separate, and you can decide about that later.
Reading is free, an account is not the same as paying. 43 compound guides, every study with its limitations written underneath, and the regimens those trials actually used. A free account opens all of it. A membership is a separate decision, and it opens the forum. What membership costs.
The wider literature
14 indexed papers and 0 registered trials mentioning Thymalin, straight from PubMed and ClinicalTrials.gov. These have not been read by us. Unlike the studies above, they carry no findings and no limitations written by anyone here, because writing either would mean claiming a reading nobody has done. They are a starting point for yours.
El-Idrissi A, et al.FASEB bioAdvances2026PMID 41624337
journal article
Zimecki M, et al.International immunopharmacology2023PMID 36963263
journal article
Avolio F, et al.International journal of molecular sciences2022PMID 35408963
journal article
Tursi A, et al.Reviews on recent clinical trials2021PMID 34126909
journal article
Stasenko AA, et al.Klinichna khirurhiia2014PMID 25417290
english abstractjournal article
Khavinson VKh, et al.Advances in gerontology = Uspekhi gerontologii2013PMID 24003726
english abstractjournal articlereview
Tsybikov MN, et al.Khirurgiia2012PMID 23258355
english abstractjournal article
Zimecki M, et al.Folia neuropathologica2010PMID 21225507
journal articleresearch support, non-u.s. gov't
Khavinson VKh, et al.Advances in gerontology = Uspekhi gerontologii2002PMID 12577695
english abstractjournal articlereview
Dardenne M, et al.Metal-based drugs1994PMID 18476235
journal article
Skotnicki ABMedical oncology and tumor pharmacotherapy1989PMID 2657248
journal articlereview
Solinger AMPharmacotherapy1987PMID 3299294
journal articlereview
Alexandrova AE, et al.Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Pneumoftiziologia1981PMID 6264576
english abstractjournal article
Brand A, et al.Science (New York, N.Y.)1976PMID 180600
journal articleresearch support, u.s. gov't, p.h.s.
Thymalin has its own forum, split by the same six categories as the rest of the site.
The oldest record the importer found for Thymalin is from 1976. The newest is 2026. That is…
Members only. Join to read the rest
Membership
The guide above is open to everyone, and the literature underneath it opens with a free account. That is the educational half of this site. Reading and joining the discussion around Thymalin, and every other entry, is what membership pays for.
For Research & Educational Discussion Only. Not Medical Advice
This guide is educational reference material compiled from published literature. It is not medical advice, not a recommendation, and not a substitute for a clinician who knows your history. Nothing here should be used to make a decision about your own health without one.
Talk to a licensed healthcare professional.